For the quarter ending 2025-09-30, IKT made $14,099,293 in revenue. -$11,930,280 in net income. Net profit margin of -84.62%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| Research and development | 7,649,697 | 5,270,967 | 4,302,637 | |
| Selling, general and administrative | 5,611,503 | 5,919,731 | 2,844,630 | |
| Change in fair value contingent consideration | 492,827 | 358,420 | - | |
| Total costs and expenses | 12,768,373 | 10,832,278 | 7,147,267 | |
| Loss from operations | -12,768,373 | -10,832,278 | -7,147,267 | |
| Interest income | 838,093 | 916,755 | 267,295.5 | |
| Net loss | -11,930,280 | -9,915,523 | -6,879,971.5 | |
| Net loss per share - basic | -0.13 | -0.11 | -0.29 | |
| Net loss per share - diluted | -0.13 | -0.11 | -0.29 | |
| Weighted average number of shares outstanding, basic | 90,050,973 | 90,009,625 | 5,928,055 | |
| Weighted average number of shares outstanding, diluted | 90,050,973 | 90,009,625 | 5,928,055 | |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)